Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
12.16
+0.16 (+1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024
From
Alvotech
Via
GlobeNewswire
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Exposures
Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
February 26, 2024
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.
Via
Benzinga
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech's Earnings: A Preview
November 27, 2023
Via
Benzinga
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 15, 2024
From
Alvotech
Via
GlobeNewswire
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
January 29, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024
From
Alvotech
Via
GlobeNewswire
3 mid-caps under $20 that Wall Street loves
January 23, 2024
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 28, 2023
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For November 28, 2023
November 28, 2023
Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion.
Via
Benzinga
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
November 21, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 14, 2023
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
November 10, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
Alvotech
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
October 20, 2023
Via
Benzinga
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
October 12, 2023
From
Alvotech
Via
GlobeNewswire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Kashiv Biosciences LLC
Via
Business Wire
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
September 25, 2023
From
Alvotech
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023
September 21, 2023
Via
Benzinga
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Changes to the Leadership Team
September 05, 2023
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.